Santos R F, Palmieri M G, Wajchenberg B L, Azhar S
Laboratory of Human Nutrition and Metabolic Diseases, School of Medicine, University of São Paulo, Brazil.
Horm Metab Res. 1994 Jun;26(6):283-7. doi: 10.1055/s-2007-1001684.
We have examined insulin binding, and insulin receptor associated tyrosine kinase activity in detergent solubilized and Ricin II-agarose purified receptor preparations from erythrocytes of obese and non-obese subjects with normal glucose tolerance and non-obese patients with NIDDM. Insulin receptor activity, as assessed by [125I Tyr A14] insulin binding, was significantly lower in erythrocyte preparations from the obese group when compared with similar preparations from non-obese subjects, with either normal glucose tolerance or NIDDM. The affinity of the receptor for insulin, however, was reduced in both obese subjects and patients with NIDDM as compared to non-obese subjects with normal glucose tolerance. Insulin receptor tyrosine kinase activity, measured in the absence (basal) and presence of insulin (0.3-3000 nM), was decreased in obese and NIDDM subjects with normal glucose tolerance and in patients with NIDDM. Insulin sensitivity, measured as the dose of insulin required for half-maximal activation of kinase activity, however, was comparable among three groups. In contrast, insulin-stimulated tyrosine kinase activity, when normalized to insulin binding activity, was unchanged in both non-obese and obese subjects with normal glucose tolerance, but was reduced approximately 60% in the NIDDM group. These findings indicate that the functional behavior of insulin receptor-kinase signaling system is markedly impaired in non-obese patients with NIDDM. Furthermore, the insulin receptor-tyrosine kinase defect (i.e. decrease in activity) observed in patients with NIDDM is probably related to a reduction in coupling efficiency between insulin binding and the activation of the receptor tyrosine kinase activity.
我们检测了肥胖且糖耐量正常的受试者、非肥胖且糖耐量正常的受试者以及非肥胖型非胰岛素依赖型糖尿病(NIDDM)患者红细胞中,经去污剂溶解并用蓖麻毒素II -琼脂糖纯化的受体制剂中的胰岛素结合情况以及与胰岛素受体相关的酪氨酸激酶活性。通过[125I Tyr A14]胰岛素结合评估的胰岛素受体活性,与非肥胖受试者(无论糖耐量正常与否或患有NIDDM)的类似制剂相比,肥胖组红细胞制剂中的活性显著降低。然而,与糖耐量正常的非肥胖受试者相比,肥胖受试者和NIDDM患者体内受体对胰岛素的亲和力均有所降低。在无胰岛素(基础状态)和有胰岛素(0.3 - 3000 nM)存在的情况下测量的胰岛素受体酪氨酸激酶活性,在肥胖且糖耐量正常的受试者以及NIDDM患者中均降低。然而,以激酶活性半最大激活所需的胰岛素剂量衡量的胰岛素敏感性,在三组之间相当。相比之下,将胰岛素刺激的酪氨酸激酶活性标准化为胰岛素结合活性后,糖耐量正常的非肥胖和肥胖受试者中该活性未发生变化,但在NIDDM组中降低了约60%。这些发现表明,非肥胖型NIDDM患者中胰岛素受体 - 激酶信号系统的功能行为明显受损。此外,在NIDDM患者中观察到的胰岛素受体酪氨酸激酶缺陷(即活性降低)可能与胰岛素结合和受体酪氨酸激酶活性激活之间的偶联效率降低有关。